TheraRadar
← Back
Data updated: Mar 29, 2026

CHARTWELL INJECTABLE

RespiratoryInfectious DiseaseCardiovascular
Generics

CHARTWELL INJECTABLE is a generic drug manufacturer focused on Respiratory, Infectious Disease, Cardiovascular.

1997
Since
6
Drugs
-
Trials
7
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

PROPRANOLOL HYDROCHLORIDE 2026-01-27
PROPRANOLOL HYDROCHLORIDE 2025-05-08
Labeling
ACYCLOVIR SODIUM 2025-02-18
Labeling
PROPRANOLOL HYDROCHLORIDE 2024-10-09
Labeling
PROPRANOLOL HYDROCHLORIDE 2024-08-23
Labeling
PROPRANOLOL HYDROCHLORIDE 2024-07-11
Labeling
ACYCLOVIR SODIUM 2024-06-25
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 40%
2 drugs
Infectious Disease 20%
1 drugs
Cardiovascular 20%
1 drugs
Neurology 20%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Respiratory
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Neurology, Respiratory
GSK big-pharma
Infectious Disease, Respiratory, Neurology
APOTHECON specialty
Infectious Disease, Cardiovascular, Respiratory
ACTELION big-pharma
Cardiovascular, Respiratory, Neurology, Infectious Disease